Phase 1 Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies.

CONCLUSIONS: TTI-621 was well tolerated and demonstrated activity as monotherapy in patients with R/R B-NHL and T-NHL and combined with rituximab in patients with R/R B-NHL.
PMID: 33451977 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 15, 2021 Category: Cancer & Oncology Authors: Ansell SM, Maris M, Lesokhin AM, Chen R, Flinn IW, Sawas A, Minden MD, Villa D, Percival MM, Advani AS, Foran JM, Horwitz S, Mei M, Zain J, Savage KJ, Querfeld C, Akilov OE, Johnson LD, Catalano T, Petrova PS, Uger RA, Sievers EL, Milea A, Roberge K, Shou Tags: Clin Cancer Res Source Type: research